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Abstract Cushing’s disease (CD) is a condition of chronic
hypercortisolism caused by an adrenocorticotropic hor-
mone-secreting pituitary adenoma. First-line transsphenoi-
dal surgery is not always curative and disease sometimes
recurs. Radiotherapy often requires months or years to be
effective, and is also not curative in many cases. Conse-
quently, effective medical therapies for patients with CD are
needed. Corticotroph adenomas frequently express both
dopamine (D2) and somatostatin receptors (predominantly
sstr5). Pasireotide, a somatostatin analog with high sstr5
binding affinity, has shown urinary free cortisol (UFC)
reductions in most patients with CD in a large phase 3 trial,
with UFC normalization and tumor shrinkage in a subset of
patients. Adverse events were similar to other somatostatin
analogs, with the exception of the degree and severity of
hyperglycemia. Two small trials (one prospective and one
retrospective) have suggested that cabergoline, a D2 receptor
agonist, could be effective in normalizing UFC, but current
long-term data results are conflicting. Combination treat-
ment with pasireotide plus cabergoline and the adrenal ste-
roidogenesis inhibitor ketoconazole has been successful, but
further investigation in larger trials is necessary. Retinoic
acid also showed interesting results in a recent very small
prospective study. Glucocorticoid receptor blockade with
mifepristone has recently demonstrated improvement in
signs and symptoms of Cushing’s and glycemic control;
however, this modality does not address the etiology of the
disease and has inherent adverse events related to its mech-
anism of action. Pituitary-targeted medical therapies will
soon play a more prominent role in treating CD, and may
potentially become first-line medical therapy when surgery
fails or is contraindicated.
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Introduction
Cushing’s disease (CD) is a condition of hypercortisolism
caused by an adrenocorticotropic hormone (ACTH)-
secreting pituitary adenoma. While rare, it is associated
with significant morbidity and mortality [1–3].
Pituitary secretion of ACTH is normally regulated by
hypothalamic and paracrine signals, and through negative
feedback by glucocorticoids [4]. Systemic ACTH levels also
exhibit a circadian rhythm, controlled by the suprachias-
matic nucleus and entrained by light–dark cycles [4].
Superimposed on this circadian rhythm is an ultradian cycle
of pulsatile ACTH release, which is closely mimicked by
cortisol levels (Fig. 1a) [5–7]. In patients with CD, both
basal and peak ACTH levels are elevated (Fig. 1b), and
ACTH and cortisol levels are uncoordinated [5–10].
For most patients with CD, primary treatment is trans-
sphenoidal surgery to remove the pituitary adenoma.
However, success rates are variable (reported as 65 to
90 %) and dependent on the surgeon’s expertise [11].
Published 5- and 10-year recurrence rates are as high as 25
and 56 %, respectively [12, 13], and many patients develop
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deficiencies of other pituitary hormones post-surgery [11].
Patients who fail to achieve or maintain remission require
secondary treatment, including radiotherapy and/or adre-
nalectomy—both of which are associated with subsequent
hormone deficiencies [11]. Thus, additional treatment
options for patients with CD are required.
While there are several potential CD therapeutic targets,
there is relatively little clinical experience with most
medical treatments. Recently, however, prospective studies
have demonstrated promise for pituitary-directed medical
interventions targeting the underlying adenoma.
Potential pituitary targets and pituitary-targeted
therapies for corticotroph adenomas
Somatostatin receptors in the pituitary and pituitary
adenomas
Somatostatin often serves to inhibit secretory responses,
but also exhibits antiproliferative effects in some tissues
[14]. Somatostatin receptors are widespread throughout the
central nervous system and in several peripheral tissues
[15, 16]. To date, 5 somatostatin receptor subtypes (sstr)
have been identified and cloned (sstr1–sstr5) [14]. Immu-
nostaining indicates that normal human anterior pituitary
expresses all 5 subtypes, and that most corticotroph ade-
nomas express C1 sstr [17–19]. While expression levels are
highly variable, sstr2 and sstr5 are most consistently
expressed, and sstr4 is generally absent [17, 19]. A study
using quantitative RT-PCR and immunohistochemistry
found that human corticotroph adenomas expressed sstr1,2,4
and 5, and that sstr5 had the highest expression levels in
10/12 adenomas [20].
Differential sstr expression levels between somatotroph
and corticotroph adenomas may partly explain why octre-
otide, which has relative selectivity for sstr2, inhibits
growth hormone secretion from somatotroph adenomas but
has little effect on ACTH secretion from corticotroph
adenomas [19]. Somatostatin has also been shown to
inhibit ACTH secretion from pituitary cells taken from
adrenalectomized rats [21], and reduced serum ACTH
levels in humans who had hypocortisolism [22–24], but did
not affect ACTH secretion from pituitary cells taken from
normal rats [25, 26] or ACTH levels in patients with CD
[17, 19, 27–29]. These findings suggested that high corti-
costeroid levels were associated with low responsiveness to
sstr2-specific analogs in corticotroph adenomas. This con-
clusion is supported by the observation that the ability of
somatostatin or octreotide to inhibit ACTH secretion from
cultured corticotroph adenoma cells was abolished by
pretreatment with dexamethasone [30].
These findings have produced a working model of the
regulation of ACTH secretion by corticotroph adenomas
[31, 32], wherein high systemic cortisol downregulates
sstr2 expression in the corticotroph adenoma cells, ren-
dering sstr2 agonists ineffective at inhibiting ACTH
secretion. In contrast, sstr5 expression appears to be rela-
tively unaffected by high cortisol levels. Upon treatment
with an sstr5 agonist, ACTH secretion is reduced, leading
to declines in cortisol secretion from the adrenal glands.
This model is supported by evidence from murine AtT20
cells, a corticotroph cell line. Treatment of AtT20 cells
with dexamethasone reduced expression of sstr2 mRNA
without significantly affecting sstr5 mRNA expression or




Generally, somatostatin analogs are designed to emulate
the structure of native somatostatins, while lacking the
Fig. 1 24-hour plasma levels of ACTH (dotted line) and cortisol
(solid line) in a normal female (a) and a female patient with Cushing’s
disease (b). Note that in CD, both basal and peak cortisol levels are
elevated, and cortisol secretion is less synchronized to ACTH levels.
From Roelfsema F, Pincus SM, Veldhuis JD (1998) J Clin Endocrinol
Metab, volume 83, page 690 [7]. Reproduced with permission
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enzyme degradation sites of the native molecules. Octre-
otide and lanreotide (Fig. 2a, b) have long been used for
treatment of acromegaly, hyperthyroidism, and gastroen-
teropancreatic neuroendocrine tumors. Another novel
analog, somatoprim (DG3173), selectively binds sstr sub-
types 2, 4, and 5 and has demonstrated suppression of
growth hormone in octreotide-non-responsive cultured
human somatotroph adenomas [34]. However, the clinical
utility of somatoprim has not yet been evaluated.
Table 1 [35–38] summarizes binding affinities (IC50) for
somatostatin-14 and for 5 somatostatin analogs. Somata-
stain-14 binds to all 5 sstrs with similar binding affinity,
while both octreotide and lanreotide exhibit relative
selectivity for sstr2. This selectivity profile is consistent
with studies that have ascribed the efficacy of octreotide
and lanreotide at inhibiting growth hormone release from
somatotroph adenomas to their activity at sstr2 [39].
Pasireotide
Overview
Pasireotide is a cyclic hexapeptide that was discovered
using a rational approach to design a stable somatostatin
analog with a receptor selectivity profile resembling that of
native somatostatin. Pasireotide (Fig. 2c), has high affinity
for sstr1,2,3 and 5 (Table 1), with much higher affinity for
subtypes 1 and 5, and lower affinity for subtype 2, com-
pared with octreotide [40]. In preclinical studies, pasireo-
tide demonstrated inhibition of ACTH secretion in cultured
human corticotroph adenomas [19, 20] and in murine
AtT20 cells [17, 19]; one study has also reported reduced
cell proliferation in cultured human corticotropinomas
[20]. Compared with octreotide, pasireotide demonstrated
greater suppression of CRH-stimulated ACTH release from
AtT20cells [17, 19]. Further, consistent with the model of
glucocorticoid-mediated downregulation of sstr2, pretreat-
ment of AtT20 cells with dexamethasone abolished the
inhibitory effects of octreotide on ACTH secretion, but had
no effect on the inhibitory action of pasireotide or
somatostatin-14 [33]. Together, these findings support the
conclusion that pasireotide inhibits ACTH secretion from
corticotroph adenomas by acting predominantly at sstr5.
Subsequent supportive in vivo results [41, 42] established
the rationale for studies on the use of pasireotide in patients
with CD.
Fig. 2 Chemical structures of somatostatin-14, octreotide, and
pasireotide. Adapted from Bruns C, Lewis I, Briner U, Meno-Tetang
G, Weckbecker G (2002) European Journal of Endocrinology,
volume 146, page 710 [38]. Reproduced with permission
Table 1 Binding affinities (IC50) for various somatostatin analogs at
the 5 known somatostatin receptor subtypes
Binding affinity (IC50), nmol/L
Analog sstr1 sstr2 sstr3 sstr4 sstr5
Somatostatin-14 0.93 0.15 0.56 1.5 0.29
Octreotide 280 0.38 7.1 [1000 6.3
Lanreotide 180 0.54 14 230 17
Vapreotide [1000 5.4 31 45 0.7
Pasireotide 9.3 1.0 1.5 [100 0.16
Somatoprim [35] [1000 3 [100 7 6
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Clinical trial experience with pasireotide in Cushing’s
disease
After promising results in a 15-day Phase 2 trial [40], a ran-
domized, double-blind phase 3 trial of pasireotide was con-
ducted in adult patients with de novo, persistent, or recurrent
CD (UFC C1.59 upper limit of normal [ULN]) who were not
candidates for surgery and with no pituitary radiotherapy in
the preceding 10 years. Eligible patients (N = 162) were
randomized to receive 600 or 900 mcg of pasireotide twice
daily for an initial period of 3 months. After 3 months, those
with UFC\baseline and\29 ULN continued blinded therapy
for another 3 months. Other patients were unblinded, and their
dose was increased by 300 mcg twice daily. At 6 months, all
patients entered the open-label phase of the study and could
have their dose increased again to a maximum of 1200 mcg
twice daily, if necessary [43].
Figure 3 shows changes from baseline to 6 months in UFC
levels for patients in the two dose groups of the phase 3 trial.
The majority of patients had declines in UFC levels at
6 months; 6 patients had increases. At 6 months, 15 % of
patients in the 600 mcg group and 26 % of patients in the
900 mcg group met the primary endpoint of UFC level within
the normal range without dose increase. Median percentage
changes in UFC levels from baseline to 6 months were -
47.9 % in the 600 mcg group and -47.9 % in the 900 mcg
group. Among the 36 patients who achieved normalization of
UFC levels at 6 months, 20 maintained normal levels at
12 months, including some patients who had dose reductions.
Moreover, patients who responded to treatment could gener-
ally be identified within the first 2 months of treatment [43].
Mean plasma ACTH levels and serum and salivary
cortisol levels were reduced at both 6 and 12 months, and
patients had significant improvements in signs and symp-
toms of hypercortisolism during the trial, including
reductions in systolic and diastolic blood pressure, tri-
glycerides, low-density lipoprotein cholesterol, and body
weight. The time-course of many of these improvements
closely followed the time-course UFC reduction. Patients
also reported significant increases in health-related quality
of life. Finally, among the 75 patients who had measurable
pituitary tumors on magnetic resonance images at baseline,
tumor volume changed by an average of -9.1 and
-43.8 % in the 600 and 900 mcg groups, respectively [43].
Hyperglycemia-related adverse events occurred in 118 of
162 patients (73 %), and 10 patients discontinued because of
such events. Twenty one patients (13 %) had grade 3 or 4
hyperglycemia, and 74 patients initiated a new antidiabetic
medication during the study [43]. While no glycemic
intervention studies have been completed in pasireotide-
treated CD patients, the mechanism of pasireotide-induced
hyperglycemia was investigated in 90 healthy volunteers
[44]. Results indicate that pasireotide-induced hyperglyce-
mia is mediated by a reduction in secretion of insulin and
incretin hormones glucagon-like peptide-1 (GLP-1) and
gastric inhibitory polypeptide (GIP). Glucagon secretion was
only mildly inhibited, and pasireotide appears to have no
effect on peripheral or hepatic insulin sensitivity in healthy
individuals. Treatment with the GLP-1 analog liraglutide or
the dipeptidyl peptidase 4 (DPP-4) inhibitor vildagliptin was
most effective in countering hyperglycemia in this popula-
tion, while metformin and nateglinide had little effect.
Patients with CD, however, are often insulin-resistant. A
recently published proposal for management of hypergly-
cemia in patients with CD treated with pasireotide rec-
ommends metformin as first-line medical treatment for CD
patients who develop new or worsening hyperglycemia
with pasireotide, with an adjunctive DPP-4 inhibitor, sul-
fonylurea/glinide, and/or GLP-1 analog as required to
achieve glycemic control. Metformin plus insulin is rec-
ommended if such combination therapy is not tolerated or
insufficient and early intervention with insulin is recom-
mended on a case-by-case basis [45].
Other than the degree and severity of hyperglycemia-
related events, the safety and adverse event profiles of
pasireotide in the phase 3 trial were similar to those
observed with other somatostatin analogs. Other common
adverse events were diarrhea (58 %), nausea (52 %),
cholelithiasis (30 %), headache (28 %), and abdominal
pain (24 %). Among the 137 patients who had a normal
gallbladder at baseline, 27 had gallstones at their latest
assessment and 6 had a cholecystectomy [43]. Pasireotide
was recently approved in the US [46] and Europe [47] for
the treatment of adult CD patients for whom pituitary
surgery is not an option or has failed.
Dopamine receptors and dopamine receptor agonists
Like somatostatin receptors, dopamine receptors are widely
expressed in normal neuro-endocrine tissues and pituitary
Fig. 3 Changes in UFC levels from baseline to 6 months in
individual patients in the phase 3 trial of pasireotide. The dashed
black line represents the upper limit of the normal range for UFC.
From Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F,
Maldonado M, et al., for the Pasireotide B2305 Study Group (2012) N
Engl J Med, volume 366, page 918 [43]. Reproduced with permission
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adenomas, including approximately 80 % of corticotroph
adenomas [48, 49]. Five dopamine receptor subtypes have
been characterized, usually classified as D1-like or D2-like,
with most D2-like receptors associated with inhibitory
actions [50]. The dopamine agonists bromocriptine and
cabergoline have both been used to treat pituitary adeno-
mas; however, cabergoline is more selective at D2 recep-
tors and has been found to be more effective and better
tolerated than bromocriptine in women receiving treatment
for hyperprolactinemia [51].
In clinical studies, bromocriptine has had small and
variable effects on ACTH secretion in patients with CD
[50]. In contrast, a 2004 study demonstrated significant
in vitro inhibition of ACTH secretion with cabergoline in
100 % of cases with confirmed D2 receptor expression, and
significant in vivo reduction of cortisol levels in 60 % of
cases—with 40 % normalization of cortisol secretion [48].
Altogether, 3 small, non-randomized studies (one with a
long-term follow-up publication) have found evidence
have found evidence for efficacy of cabergoline in this
setting [48, 52, 53].
In a study of 10 patients, 6 achieved UFC normalization
after 3 months’ treatment with cabergoline, and 2 addi-
tional patients achieved significant UFC reductions [48]. In
a follow-up to this investigation, 20 patients were enrolled
who had CD unsuccessfully treated by surgery [53]. After
3 months of cabergoline (1 mg/week with dose adjusted to
a maximum of 7 mg/week), 7 patients (35 %) achieved
eucortisolism and an additional 8 (40 %) experienced
C25 % decline in UFC. The 8 partial responders all had
dose increases, and 6 of these had normal UFC after
6–12 months. However, 5 patients who achieved normal
UFC levels either initially or after dose increase escaped
from treatment control. Thus, at 12 months, 10 patients
(50 %) had normal UFC levels. However, 2 of these
patients subsequently discontinued treatment because of
severe asthenia, resulting in a long-term control rate of
40 %. Most responders exhibited improvements in signs
and symptoms of CD, including significant mean declines
in blood pressure, waist/hip ratio, serum glucose, and
tumor volume, and significant improvements in b-cell
function.
Similar supportive results were found in a retrospective,
non-randomized analysis of 30 patients with CD in Buenos
Ares and Montreal who received cabergoline (initially
0.5–1.0 mg/week adjusted to a maximum of 6 mg/week) for
up to 5 years [54]. Within 3–6 months, 11 patients (37 %)
achieved sustained normalization of UFC (C2 normal values
measured at 1–3 months apart; complete response). Nine of
these patients achieved long-term UFC normalization after a
mean of 37 months (range, 12–60) on a mean cabergoline
dose of 2.1 mg/week. Four patients (13 %) achieved UFC
\125 % ULN (partial response) within 3–6 months of
cabergoline initiation, but none of these patients experienced
long-term response. Escape from response was observed in 2
patients with long-term complete response after 2 and
5 years of treatment, although one patient transiently
renormalized after cabergoline dose increase. Long-term
tolerability was positive; no serious adverse events were
reported during treatment. No symptoms of cardiovascular
dysfunction were reported and no patients presented symp-
tomatic adrenal insufficiency.
Although the results of these small studies have shown
promise for the use of cabergoline as medical therapy for
CD, no large-scale, double-blind trials have been con-
ducted. Thus, it is difficult to draw conclusions about the
overall efficacy and safety of this approach.
One potential concern regarding the use of DA agonists
for CD has been the association of long-term ergot deriva-
tives with increased risk of valvular heart disease [55–57].
However, this risk was identified in studies performed in
patients using DA agonists for Parkinson’s disease at doses
considerably higher (often [3 mg/day) than those used in
CD (generally\7 mg/week). Schade et al. [56] reported that
the relative risk of valvular heart disease was 50.3 (95 % CI
6.6–381.4) in patients receiving[3 mg/day compared to 2.6
(95 % CI 0.5–12.8) in patients receiving \3 mg/day. Fur-
thermore, a study of 78 patients receiving DA agonists
(including 47 who were using cabergoline) for an average of
8 years for prolactinoma found an increased risk of aortic
valve calcification and mild tricuspid regurgitation, but no
increase in the risk of clinically relevant valvular heart
disease compared to control patients [58]. Among patients
receiving cabergoline, the mean duration of therapy was
5.2 ± 0.4 years and the mean cumulative dose was
363 ± 55 mg. There was no relation between cumulative
dose of cabergoline and the presence of mild, moderate or
severe valve regurgitation. Thus, the evidence suggests that
valvular heart disease associated with long-term use of DA
agonists is much less of a concern for patients using the
doses typical of treatment regimens for CD. A summary of
current prospective studies with pituitary targeted medical
therapy is provided in Table 2 [40, 43, 48, 52, 53, 59].
Other investigational therapies
Combination somatostatin analog-dopamine agonist
Combined use of a somatostatin analog and a dopamine agonist
for treatment of CD has been proposed on the basis of similar
studies suggesting additive effects on growth hormone secre-
tion from somatotroph adenomas [60]. In a study of 17 patients
with CD, pasireotide monotherapy (100–250 mcg three times a
day) normalized UFC levels in 5 patients, and addition of ca-
bergoline (0.5–1.5 mg every other day) normalized UFC levels
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in 4 more patients. Among the remaining 8 patients, subsequent
addition of ketoconazole (200 mg three times a day) normal-
ized UFC levels in 6, leaving only 2 patients who still had
elevated UFC levels. Thus, sequential therapy using these three
agents shows promise but requires further studies of both
efficacy and safety [61].
Temozolomide monotherapy and in combination
Temozolomide, an oral alkylating agent typically used in
chemotherapeutic treatment of astrocytoma and melanoma,
has shown promise as monotherapy [62, 63], and in com-
bination with pasireotide [64], as a treatment for aggressive
pituitary adenomas and carcinomas.
To date, *30 cases of pituitary adenoma have been
treated with temozolomide (including ten ACTH-secreting
adenomas). Overall reported response rate is approximately
60 % [62, 63]; however, information on temozolomide
treatment of pituitary adenomas is currently confined to
individual case reports and three case series [65–67]. An
inverse relationship between tumoral O6-methylguanine-
DNA methyltransferase (MGMT) immunoexpression and
response to temozolomide therapy has been suggested, but
not confirmed in all studies [62, 65, 67, 68].
Temozolomide may represent a viable treatment option
for aggressive corticotroph adenomas refractory to surgery,
radiotherapy, or other medical treatment. In tumors that
responded to temozolomide, the clinical response was
associated with prompt reductions in ACTH, chiasmatic
compression and mass effects. Thus, it is possible to
evaluate response early in the course of treatment. Targeted
modulation of MGMT expression may be useful in patients
who may otherwise not respond to temozolomide therapy
[63].
Retinoic acid
The retinoic acid receptor is a type II nuclear receptor
involved with transcriptional regulation. In a murine cor-
ticotrope tumor cell line, retinoic acid has been shown
to reduce ACTH secretion and pro-opiomelanocortin
(POMC) synthesis. Further, there is evidence that, with
prolonged treatment, retinoic acid induces increased cas-
pase-3 activity and cell death in ACTH-secreting cells. It
has also demonstrated inhibition of corticosterone pro-
duction and cell proliferation in adrenal cortex cells
[69]. Retinoic acid had demonstrated reduced ACTH
secretion and prevented tumor growth in mice with
implanted with tumoral corticotropes [70]. In a 6-month
study in dogs with spontaneous corticotrope tumors, reti-
noic acid reduced cortisol excess and improved associated
symptoms [71].
A recent small study showed a marked reduction in UFC
levels in 5/7 patients (22–73 % of baseline values), and
UFC normalization in three patients. There was no appar-
ent pattern of decrease in plasma cortisol. Plasma ACTH
decreased in the first month of treatment and then returned
to pretreatment levels in responsive patients. Blood pres-
sure, glycemia, and signs of hypercortisolism improved on
treatment. Patients reported only mild adverse effects (e.g.,
xerophthalmia and arthralgias) [59].
EGFR
The epidermal growth factor receptor (EGFR) family has
recently been studied as a therapeutic target for CD. In cul-
tured human and canine corticotroph tumors, gefitinib (an
EGFR tyrosine kinase inhibitor) attenuated POMC expres-
sion, inhibited corticotroph tumor cell proliferation, and
Table 2 Medical treatments for Cushing’s disease evaluated in prospective clinical studies
Compound Trial Patients (N) Treatment
duration
Outcome
Pasireotide Boscaro et al. [40] 29 15 days 5/29 patients (17 %) achieved UFC B ULN; 22/29 patients
(76 %) experienced reduction in mean UFC
Colao et al. [43] 162 12 months 33/162 patients (20 %) achieved UFC B ULN within
6 months without increase from randomized dose; the
majority of patients experienced reduction in UFC at month
6, sustained through month 12
Cabergoline Lila et al. [52] 18 5 months 5 patients (28 %) achieved MNSC \5 lg/dL or low-dose
dexamethasone-suppressed serum cortisol \1.8 lg/dL
Pivonello et al. [48, 53] 20 3–24 months After 3 months, 15 patients (75 %) achieved UFC B ULN or
C25 % reduction from baseline; 8 patients (40 %)
maintained UFC B ULN at 24 months
Retinoic acid Pecori Girald et al. [59] 7 6–12 months 3/7 patients (43 %) achieved UFC B ULN; 5/7 patients (71 %)
experienced reduction in UFC
MNSC midnight salivary cortisol, UFC urinary free cortisol, ULN upper limit of normal
6 J Neurooncol (2013) 114:1–11
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induced apoptosis. In murine studies, gefitinib decreased
tumor size and corticosterone levels, and reversed signs of
hypercortisolemia, including elevated glucose levels and
excess omental fat [72]. These results indicate that inhibiting
EGFR signaling may be a valuable strategy for treating CD.
Further studies evaluating clinical efficacy and safety in
patients with CD are needed.
Doxazosin
The selective alpha(1)-adrenergic receptor antagonist,
doxazosin has been shown to decrease plasma ACTH and
inhibit proliferation in human and murine pituitary tumor
cells, and may represent a potentially useful treatment
option in pituitary adenomas [73]. However, there is cur-
rently no clinical experience with doxazosin, and more data
are required before any such treatment strategy could be
advocated.
Other medical treatment modalities in Cushing’s
disease
Mifepristone: glucocorticoid receptor blockade
Mifepristone is a glucocorticoid receptor (GR2) antagonist,
recently FDA-approved to treat hyperglycemia in adult
patients with Cushing’s syndrome who have failed surgery
or are not surgical candidates. Regulatory approval was
based on a 24-week open-label trial studying 50 Cushing’s
patients (43 with CD) and associated type 2 diabetes
mellitus/impaired glucose tolerance (DM/IGT), or hyper-
tension [74]. At the end of the treatment period, 15/25
patients (60 %) in the DM/IGT group achieved C25 %
reductions in glucose AUC0–120 min. Patients also exhibited
reductions in HbA1c and fasting plasma glucose levels, as
well as reduced body weight and waist circumference,
improvements in clinical status and quality of life.
Fig. 4 Potential targets and
medical therapies in Cushing’s
disease. From Fleseriu, M
(2012) Neurosurg Clin N Am
volume 23, page 657 [85].
Reproduced with permission
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With GR2 receptor blockade, ACTH and cortisol will
likely increase, potentially resulting in hypokalemia,
increased blood pressure, edema, or alkalosis through
activation of mineralocorticoid receptors [75]. Other
potential adverse reactions include adrenal insufficiency
(AI) and endometrial thickening with vaginal bleeding—
both requiring close monitoring and treatment [76, 77].
As there is no biochemical marker to follow (cortisol
values are not reliable), treatment efficacy and potential
adrenal insufficiency must be gauged through changes in
clinical signs and symptoms [77]. Mifepristone is also a
potent antagonist of progesterone, thus premenopausal
women must be tested for pregnancy before administra-
tion. Caution is also warranted in combination with
drugs metabolized by CYP3A or CYP2C (e.g., simva-
statin, cyclosporine, fentanyl, ciprofloxacin, NSAIDs,
warfarin).
Adrenal-targeted drugs
Drugs inhibiting adrenocortical steroidogenesis include
ketoconazole, mitotane, etomidate and metyrapone. In
general, use of these drugs requires careful clinical moni-
toring for adverse effects, including AI [77]. Ketoconazole
has been widely used to treat CD because it inhibits several
steps in adrenal steroid synthesis and reduces UFC in the
majority of patients with CD [78]. However, it also inhibits
androgen synthesis and is associated with liver toxicity in
some patients [79]. There is little prospective information
on the long-term use of adrenal-targeted agents [11, 80];
however, 1 small retrospective study showed promising
results [81, 82]. Mitotane also inhibits several steps in
steroidogenesis, and can be adrenolytic during long-term
therapy at doses [4 g/day [77]. Because mitotane is
sequestered in adipose tissue and eliminated slowly,
pregnancy must be avoided for 5 years after discontinua-
tion [77].
LCI699 is a novel inhibitor of 11b-hydroxylase (the
final enzyme in the cortisol synthesis pathway) under
development for several indications, including CD. In a
recent proof-of-concept study in patients with CD (UFC
[1.59 ULN), all participants (N = 12) achieved either
UFC normalization or C50 % reduction from baseline after
70 days of treatment. While all patients experienced C1
AE, most were mild or moderate. Some AEs consistent
with AI were reported, and resolved after dose reduction.
Four patients experienced hypokalemia; all cases were
managed without dose reduction, and 3 patients received
oral potassium supplementation [83]. A larger-scale,
22-week expansion trial is currently underway [84]. A
summary of potential therapeutic targets in CD is shown in
Fig. 4 [85].
Conclusions and future directions
Medical therapies targeting the corticotroph adenoma rep-
resent a relatively new avenue in the long term treatment of
patients with CD who are unsuitable for surgery, or who fail
to achieve long-term disease control post-surgery [86, 87].
Drugs targeting adrenal steroid synthesis have been in use
for many years, but have not been prospectively studied and
do not target the underlying pituitary tumor. A glucocorti-
coid receptor blocker could be a valuable asset in selected
patients, but is relatively complicated to use due to absence
of a biochemical marker, and there are potential adverse
reactions inherent to mechanism of action.
Pasireotide, a multiligand somatostatin analog is the first
pituitary-directed agent shown to effectively reduce cortisol
levels and improve disease symptoms in a large, prospective,
phase 3 clinical trial. Further investigation is needed, however, to
clarify optimal management approaches for pasireotide-associ-
ated hyperglycemia. The dopamine agonist cabergoline has
shown some promise in a small, open-label trial (and one retro-
spective trial), but randomized, controlled trials with this agent
have not been conducted. A combination of lower doses of pa-
sireotide with dopamine agonists or adrenal steroidogenesis
inhibitors (e.g., a combination of low-dose pasireotide/cabergo-
line/ketoconazole) may increase the proportion of patients whose
disease can be controlled while minimizing adverse effects.
Finally, further research into patterns of receptor
expression in corticotroph adenomas may lead to increased
understanding of the pathogenesis of these tumors, and
allow development of therapies specifically tailored to
individual patients following analysis of surgical pathology.
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